ACHE and dementia: Thus, an agent that inhibits both AChE and BuChE (a dual inhibitor), such as rivastigmine, provides greater benefits to patients with dementia by decreasing the compensatory effect of Ach hydrolysis by BuChE when AChE levels decrease [11].